Researchers at the University of Michigan are developing a device that could make cancer relapse easier to spot much earlier by continuously filtering a patient’s blood for circulating tumor cells, or CTCs. These are cancer cells that break away from a tumor and travel through the bloodstream, and they can act like an early warning signal that disease has returned or may spread. Instead of relying on a standard blood draw, the system routes blood out through a catheter, passes it through a small screening chip that captures those rare cells, and then returns the filtered blood back into the vein. The idea is simple to picture: more like running all the water in a pool through a filter than testing a single cup. That matters because CTCs can be extremely scarce, so checking a larger volume of blood could improve the odds of finding them. The same captured cells might also help doctors study a patient’s tumor in more detail, including which treatments could work best. If the technology reaches the clinic, it could support earlier intervention, more personalized therapy, and perhaps one day even reduce the chance that leftover cancer cells trigger recurrence after surgery.
A blood filter for rare cancer cells
The Michigan team built a system that continuously removes blood from a vein through a catheter, moves it into a compact screening device, and then sends the blood back into the body through another catheter. Inside that device is a chip designed to catch CTCs while letting the rest of the blood pass through.
That setup tackles one of the biggest problems in liquid biopsy, the broad term for blood-based cancer testing. CTCs are often so rare that a small blood sample may miss them, even when they are clinically important. By screening blood continuously, the device aims to increase sensitivity, meaning its ability to detect even infrequent target cells.
How the device works
To make the system practical, the researchers had to move blood quickly and gently. Blood is not like water through a pipe; if flow is too rough or too slow, cells can be damaged or clots can form. So the group used its experience in microfluidics, the science of controlling tiny amounts of fluid in small channels, to design a dedicated blood pump that maintains a useful flow rate.
They also added a second pump to continuously infuse heparin, a drug that helps prevent clotting. That detail may sound mundane, but it is central to making any extended blood-processing system safe and reliable. A device like this has to do more than catch rare cells; it must do so without creating new risks for the patient.
The chip at the center
The core of the platform is a highly sensitive CTC-capturing chip that Nagrath and other University of Michigan researchers had developed previously. The chip uses antibodies, proteins that recognize specific molecular features, to pull tumor cells out of the blood. You can think of it as a molecular version of Velcro: the antibodies are chosen because they latch onto markers found on the target cells.
That approach allows the system to enrich, or concentrate, these rare cells from a much larger blood volume than a conventional test would usually examine. For early cancer detection and especially for monitoring recurrence, that could be a major advantage. A weak signal that is invisible in a small sample may become detectable when the system screens blood continuously.
Why recurrence is the first target
According to the source article, the immediate goal is to detect early recurrence in cancer survivors so clinicians can identify which patients need treatment. That is a strategically important first use. Patients who have had a tumor removed often face long stretches of uncertainty, with doctors watching for signs that disease has come back.
Today, that monitoring often depends on imaging scans, periodic blood tests, symptoms, or some combination of all three. But recurrence can begin at a microscopic level long before a scan clearly shows it. If CTCs rise before visible tumors reappear, a sensitive blood-screening device could give doctors an earlier chance to act.
From detection to personalized therapy
The device is not just about finding cancer cells. The collected CTCs could also be used for genotyping, which means analyzing their genetic makeup to see what mutations or molecular traits they carry. That information can help explain how a tumor is evolving and whether it may respond to particular drugs.
The source also notes that captured cells might be grown outside the body and tested against different treatments. In practical terms, that points toward a more personalized approach: instead of choosing therapy based only on the original tumor sample, doctors could potentially test drugs on living cancer cells taken directly from that patient’s bloodstream. It is a bit like trying several keys in a practice lock before deciding which one to use on the real door.
A modular platform beyond cancer
Nagrath’s group is also thinking beyond CTCs. They designed the system to be modular, meaning the chip can be swapped out while the device is in use. That flexibility suggests the platform could be adapted to monitor other blood-borne targets, including viruses, bacteria, or immune cells.
This matters because the hard engineering work, safely moving blood through an external device and back into the body, could support many different sensing tasks. If one chip is tuned for tumor cells and another for pathogens or immune markers, the same general machine could become a broader blood-monitoring platform rather than a single-purpose cancer tool.
Why This Matters
Early cancer detection is often framed as a search for the smallest possible signal, and this device takes a direct approach to that problem: look at much more blood. That may sound obvious, but in practice it is technically difficult, because blood has to be handled continuously, cleanly, and safely. The Michigan system brings together microfluidics, antibody-based cell capture, and real-time blood circulation in a way that could make those larger-volume searches feasible.
If successful, the platform could change care in two linked ways. First, it may help identify recurrence sooner, when intervention has a better chance of working. Second, by retrieving intact tumor cells for analysis, it may help tailor treatment to the patient’s current disease rather than relying only on older biopsy material.
What comes next
The researchers hope to pursue U.S. Food and Drug Administration approval for the device as a tool not only for CTC detection but for finding a wider range of blood-borne cells. That signals an ambition to move from a lab demonstration toward a clinically usable system. There is still a long path between promising engineering and routine hospital use, but the concept is compelling: treat blood monitoring less like a snapshot and more like a live stream. If that shift works, doctors may gain a sharper, earlier view of cancer’s return and a more precise way to decide what to do next.